Bicara Therapeutics (NASDAQ:BCAX) Shares Down 8.7% After Earnings Miss

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) fell 8.7% on Tuesday following a weaker than expected earnings announcement. The company traded as low as $13.08 and last traded at $12.95. 295,640 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 487,277 shares. The stock had previously closed at $14.19.

The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wells Fargo & Company began coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target on the stock. HC Wainwright lowered their price objective on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Wedbush reaffirmed an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Bicara Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $32.43.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in shares of Bicara Therapeutics in the first quarter worth about $326,000. Jefferies Financial Group Inc. acquired a new position in Bicara Therapeutics in the 1st quarter worth about $399,000. XTX Topco Ltd boosted its position in Bicara Therapeutics by 4.1% during the first quarter. XTX Topco Ltd now owns 28,453 shares of the company's stock worth $371,000 after purchasing an additional 1,119 shares in the last quarter. Federated Hermes Inc. boosted its position in Bicara Therapeutics by 50.0% during the first quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $156,000 after purchasing an additional 4,000 shares in the last quarter. Finally, TD Asset Management Inc grew its holdings in Bicara Therapeutics by 27.8% in the first quarter. TD Asset Management Inc now owns 130,938 shares of the company's stock valued at $1,706,000 after purchasing an additional 28,518 shares during the period.

Bicara Therapeutics Price Performance

The stock has a 50-day moving average price of $12.94 and a 200 day moving average price of $15.46.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.